EXACT Therapeutics Announces Milestone in Phase 2 Trial
EXACT Therapeutics, a promising clinical-stage precision medicine company, has recently marked a significant milestone by dosing its first patient in the pivotal ENACT trial. This Phase 2 trial explores the application of innovative Acoustic Cluster Therapy (ACT) alongside the standard treatment for pancreatic cancer, aiming to create a brighter future for patients facing this challenging disease.
The ENACT Trial: Pioneering New Treatments
The ENACT trial is an open-label, multi-centre Phase 2 study that focuses on evaluating the safety and efficacy of ACT in combination with modified FOLFIRINOX chemotherapy for patients diagnosed with borderline resectable or unresectable locally advanced pancreatic cancer. The urgency of this study arises from the alarming fact that pancreatic cancer remains one of the deadliest forms of cancer, with over 500,000 individuals diagnosed annually worldwide.
Importance of Innovative Therapies
Per Walday, the CEO of EXACT Therapeutics, expressed excitement about this new phase, noting that many patients with pancreatic cancer often face a shortage of effective treatment options. The commencement of the ENACT trial represents a proactive step toward addressing the urgent medical needs of this patient demographic, and it demonstrates the company's commitment to advancing new and potentially transformative treatment methods.
Expanding the Scope of Research
The trial will involve up to 25 participants across various locations, including the U.S., U.K., and Europe. By gathering data from a diverse patient population, the trial aims not only to assess safety but also to measure the efficacy of this novel treatment approach. The journey initiated with this trial is a beacon of hope for patients and their families.
Previous Success: Phase 1 Trial Insights
The dosing of the first patient in the ENACT trial follows promising outcomes from the Phase 1 trial, which demonstrated positive efficacy and safety results in patients with liver metastases of colorectal cancer. This background provides a solid foundation for EXPECT Therapeutics as they venture into Phase 2, armed with insights that continue to bolster their research.
What is Acoustic Cluster Therapy?
ACT, a groundbreaking technology developed by EXACT Therapeutics, leverages ultrasound and microbubbles to enhance targeted drug delivery within oncology. Such a unique approach holds the potential to broaden therapeutic applications across numerous conditions, including brain diseases. These innovations present a new horizon in cancer treatment.
Looking to the Future
As enrollment for the ENACT trial progresses, the initial safety data is anticipated to be available soon. Stakeholders and supporters alike are eager to see how the trial's results unfold, particularly in light of the pressing need for innovative treatment strategies in pancreatic cancer. With the support of Euronext Growth (EXTX), EXACT Therapeutics is positioned to make a meaningful impact in the realm of oncology and continues to push forward in clinical research.
Contact Information
For further inquiries and more information on this trial, individuals are encouraged to reach out to Per Walday, CEO of EXACT Therapeutics, via email at per.walday@exact-tx.com.
Frequently Asked Questions
What is the ENACT trial about?
The ENACT trial is a Phase 2 study investigating the safety and efficacy of Acoustic Cluster Therapy combined with standard chemotherapy for pancreatic cancer.
Who is involved in the trial?
The trial involves patients diagnosed with borderline resectable or unresectable locally advanced pancreatic cancer across the U.S., U.K., and Europe.
What is Acoustic Cluster Therapy?
ACT is a novel treatment method developed by EXACT Therapeutics that utilizes ultrasound to enhance drug delivery directly to cancer cells.
How many patients will participate in the trial?
Up to 25 patients will be enrolled in the trial to gather comprehensive data on the treatment's effectiveness.
Who can I contact for more information?
For more details, you can contact Per Walday, the CEO of EXACT Therapeutics.
